ICARIA-MM: SARCLISA + Pd
ICARIA-MM Trial Results: SARCLISA + Pomalidomide and Dexamethasone (Pd) vs Pd Alone
SARCLISA + Pd extended median PFS to ~1 year
Superior PFS with SARCLISA + Pd vs Pd alone1
At a median follow-up time of 11.6 months, 43 patients (27.9%) receiving SARCLISA + Pd and 56 patients (36.6%) receiving Pd had died. Median OS was not reached for either treatment group at interim analysis. The OS results at interim analysis did not reach statistical significance.
The median duration of treatment was
41 weeks with SARCLISA + Pd vs 24
weeks with Pd alone
GREATER THAN 40% REDUCTION IN THE RISK OF PROGRESSION OR DEATH
in patients receiving SARCLISA + Pd
mPFS=median progression-free survival; OS=overall survival.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend isatuximab-irfc (SARCLISA) for previously treated multiple myeloma2
- In combination with pomalidomide and dexamethasone (Preferred, Category 1)
- In combination with carfilzomib and dexamethasone
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
NCCN=National Comprehensive Cancer Network.
SARCLISA + Pd showed a significant
increase in ORR1
ORR: SARCLISA + Pd (95% CI: 0.52, 0.68), Pd (95% CI: 0.28, 0.43). 95% CI estimated using the Clopper-Pearson method.
CR=complete response; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.
Median time to first response was 35 days with SARCLISA + Pd vs 58 days with Pd alone among responders1